Binds Receptor Patents (Class 424/143.1)
-
Publication number: 20140134179Abstract: Antibodies that specifically bind TEM8 protein, and conjugates thereof, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.Type: ApplicationFiled: June 13, 2012Publication date: May 15, 2014Applicants: Novartis AG, The United States of America, as represented by the Sec., Dept of Health and Human ServicesInventors: Brad St. Croix, Tony Fleming, Amit Chaudhary, Saurabh Saha, Xiaoyan Michelle Zhang, Rou-fun Kwong
-
Patent number: 8722051Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: December 19, 2012Date of Patent: May 13, 2014Assignee: Immunex CorporationInventor: Steven R. Wiley
-
Patent number: 8722047Abstract: The present invention concerns compositions and methods of use of humanized anti-HLA-DR antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing CDC or ADCC. In more preferred embodiments, the humanized anti-HLA-DR antibodies bind to the same epitope of HLA-DR as, or compete for binding to HLA-DR with, a murine L243 antibody. Most preferably, the humanized anti-HLA-DR antibody exhibits a higher affinity for HLA-DR than the parental murine antibody. The humanized HLA-DR antibody is of use for therapy of various diseases such as cancer, autoimmune disease or immune dysregulatory function, and is of particular use for therapy of B cell lymphomas and leukemias. In most preferred embodiments, the humanized anti-HLA-DR antibody is capable of inducing at least partial remission of lymphomas that are resistant to other B cell antibodies, such as rituximab.Type: GrantFiled: April 5, 2010Date of Patent: May 13, 2014Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen, Chien-Hsing Chang
-
Publication number: 20140127134Abstract: Embodiments provided herein relate to methods and compositions for treating or preventing cancer. More particularly, several embodiments are drawn to treating or preventing malignant mesothelioma with antagonists of HMGB1.Type: ApplicationFiled: June 7, 2012Publication date: May 8, 2014Inventors: Haining Yang, Michele Carbone, Marco E. Bianchi
-
Publication number: 20140127207Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.Type: ApplicationFiled: January 3, 2014Publication date: May 8, 2014Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Raghida BUKHALID, Michael FELDHAUS, Anne KING, Neeraj KOHLI, Eric KRAULAND, Jeffrey David KEARNS, Alexey A. LUGOVSKOY, Ulrik NIELSEN
-
Publication number: 20140127195Abstract: Methods of, and compositions for, treating central nervous system injury with an antagonist of an alpha4 subunit containing integrin are described.Type: ApplicationFiled: January 10, 2014Publication date: May 8, 2014Applicant: BIOGEN IDEC MA INC.Inventors: Jane K. Relton, Roy R. Lobb, Eric T. Whalley, Steve P. Adams
-
Publication number: 20140127223Abstract: A monoclonal antibody that binds to an extracellular domain of human receptor-type protein tyrosine phosphatase ? (human PTPRS), or a fragment including an antigen-binding region thereof.Type: ApplicationFiled: April 27, 2012Publication date: May 8, 2014Applicant: SBI BIOTECH CO., LTD.Inventors: Tomohide Yamazaki, Jing Zhao, Koji Ishida, Yasue Shibata, Minkwon Cho, Mayuki Endo
-
Patent number: 8715665Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.Type: GrantFiled: April 11, 2008Date of Patent: May 6, 2014Assignees: The General Hospital Corporation, Dana Farber Cancer Institute, Beth Israel Deaconess Medical CenterInventors: Pasi A. Janne, Jeffrey Engelman, Lewis C. Cantley
-
Patent number: 8715670Abstract: The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.Type: GrantFiled: March 31, 2010Date of Patent: May 6, 2014Assignee: Hanwha Chemical CorporationInventors: Jung Tae Lee, Kyung Duk Moon, Ji Yong Yoon, Byung Je Sung, Dong Heon Lee, Il Sun Lee, Dong Eun Lee, Su Yeon Ryu, Young Woo Park, So Young Choi, Ji Hyun Park, Myeoung Hee Jang
-
Patent number: 8715668Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: GrantFiled: September 17, 2012Date of Patent: May 6, 2014Assignee: The UAB Research FoundationInventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
-
Patent number: 8715619Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.Type: GrantFiled: February 11, 2013Date of Patent: May 6, 2014Assignee: Cellerant Therapeutics, Inc.Inventor: Holger Karsunky
-
Patent number: 8715666Abstract: According to the invention there is provided use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA combined with at least one opioid analgesic for the preparation of a medicament for treating and/or preventing pain.Type: GrantFiled: June 23, 2011Date of Patent: May 6, 2014Assignee: Lay Line Genomics S.p.A.Inventors: Flaminia Pavone, Sara Marinelli, Antonio Cattaneo, Gabriele Ugolini
-
Patent number: 8715667Abstract: The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.Type: GrantFiled: August 15, 2012Date of Patent: May 6, 2014Assignee: Innate PharmaInventors: Karine Chemin, Laurent Gauthier, Yannis Morel, Carine Paturel, Agnes Tisserant
-
Patent number: 8715655Abstract: The present invention provides a human anti-?9 integrin antibody or an antibody fragment which specifically recognize human ?9 integrin and mouse ?9 integrin, inhibit interaction with their ligands, particularly, the antibody or antibody fragment which recognize loop regions of human and mouse ?9 integrins, a gene encoding the antibody or antibody fragment, a recombinant expression vector containing the gene, a transformant harboring the gene, production method of human anti-?9 integrin antibody or antibody fragment using the transformant, and an agent for the prophylaxis or treatment of rheumatoid arthritis which contains the antibody or antibody fragment.Type: GrantFiled: December 26, 2008Date of Patent: May 6, 2014Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Masaharu Torikai, Daisuke Ishikawa, Toshihiro Nakashima, Hirofumi Higuchi, Fumihiko Sakai, Nobuchika Yamamoto, Hirotada Fujita, Katsunari Taguchi
-
Patent number: 8715657Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12R?2 chain) as well as IL23 receptor (together with IL23R? chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: GrantFiled: March 29, 2010Date of Patent: May 6, 2014Assignee: Novartis AGInventors: Michael Bardroff, Jose M. Carballido Herrera, Daniela Della Ducata, Christoph Heusser, Ute Jaeger, Christoph Schwaerzler
-
Publication number: 20140120094Abstract: Reducing liver fibrosis in a subject having or being suspected of having a liver disease using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.Type: ApplicationFiled: October 30, 2013Publication date: May 1, 2014Applicant: National Cheng Kung UniversityInventor: Ming-Shi Chang
-
Publication number: 20140120084Abstract: Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of administering integrin beta7 antagonists, such as anti-beta7 antibodies. In addition, particular dosing regimens, including dosing regimens comprising subcutaneous administration and administration using self-inject devices are provided.Type: ApplicationFiled: September 24, 2013Publication date: May 1, 2014Applicant: GENENTECH, INC.Inventors: Banmeet Anand, Eric Stefanich, Meina Tang, Jennifer Visich, Marna Williams, Sharon O'Byrne
-
Publication number: 20140120082Abstract: The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.Type: ApplicationFiled: March 12, 2013Publication date: May 1, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: The Regents of the University of California
-
Patent number: 8709432Abstract: Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided.Type: GrantFiled: March 30, 2012Date of Patent: April 29, 2014Assignee: ImmunoGen, Inc.Inventors: Christina N. Carrigan, Kathleen R. Whiteman, Gillian Payne, Sharron Ladd
-
Patent number: 8709425Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.Type: GrantFiled: February 13, 2013Date of Patent: April 29, 2014Assignee: Biosceptre International LimitedInventors: Julia Alexander Barden, Angus Gidley-Baird
-
Patent number: 8709424Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.Type: GrantFiled: August 31, 2010Date of Patent: April 29, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Xiao Min Schebye, Grigori P. Ermakov, Douglas J. Hodges, Leonard G. Presta
-
Patent number: 8710194Abstract: The present invention relates to a single-chain variable fragment (scFv) able to recognize an epitope of the extracellular domain of CD99 human protein. The single-chain variable fragment is able to recognize and specifically and selectively bind the epitope of the extracellular domain of CD99 human protein expressed on Ewing sarcoma cells. The fragment can thus be used for the diagnosis and 10 treatment of Ewing sarcoma.Type: GrantFiled: November 12, 2010Date of Patent: April 29, 2014Assignee: Istituto Ortopedico RizzoliInventors: Piero Picci, Katia Scotlandi, Alessandro Ascione, Maurizio Cianfriglia, Maria Luisa Dupuis, Michela Flego, Mara Gellini, Alessandra Mallano
-
Publication number: 20140115727Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor both in a ligand-dependent and in a ligand-independent manner, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: August 29, 2013Publication date: April 24, 2014Applicant: Pierre Fabre MedicamentInventors: Liliane Goetsch, Thierry Wurch, Cedric Bes
-
Publication number: 20140112931Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.Type: ApplicationFiled: May 21, 2012Publication date: April 24, 2014Applicants: UNIVERSITE DE MONTPELLIER 1, CENTRE VAL D'AURELLE - PAUL LAMARQUEInventors: Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege Gaborit, Yassamine Lazrek
-
Patent number: 8703125Abstract: The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of mental and behavioral disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention further-more relates to methods of altering expression of said receptors in vivo.Type: GrantFiled: December 17, 2009Date of Patent: April 22, 2014Assignee: H. Lundbeck A/SInventors: Simon Glerup Pedersen, Ulrich Bølcho, Kimmo Jensen, Anders Nykjær
-
Patent number: 8703139Abstract: Disclosed are monoclonal antibodies, binding fragments, and derivatives thereof directed to the human melanocortin-4 receptor, as well as pharmaceutical compositions including the same, the therapeutic uses, including methods for treating cachexia and related conditions and diseases, using such monoclonal antibodies, binding fragments, derivatives, and pharmaceutical compositions.Type: GrantFiled: July 27, 2012Date of Patent: April 22, 2014Assignee: Universitaet BaselInventors: Karl Hofbauer, Jean Christophe Peter
-
Publication number: 20140105898Abstract: This invention relates generally to methods and agents for modulating adiposity-related conditions. More particularly, the present invention relates to the use of TRAIL death receptor agonists, including nucleic acids such as TRAIL polynucleotides, peptides and polypeptides including TRAIL polypeptides, TRAIL DR agonist antigen-binding molecules, TRAIL DR peptide agonists as well as small molecule TRAIL DR agonists in compositions and methods for treating or preventing adiposity-related conditions such as obesity, diabetes mellitus and metabolic syndrome.Type: ApplicationFiled: February 27, 2012Publication date: April 17, 2014Applicant: Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo GaroInventors: Merlin C. Thomas, Giorgio Zauli, Paola Secchiero, Bruno Fabris, Stella Bernardi
-
Publication number: 20140105907Abstract: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.Type: ApplicationFiled: September 4, 2013Publication date: April 17, 2014Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Nobuaki Takahashi, Toru Miura, Yoshinori Kitagawa, Aki Matsushima
-
Publication number: 20140105821Abstract: A monoclonal antibody is described herein specifically binding to domains II and IIIc of FGFR1 or to a complex of fibroblast growth factor receptor type 1 and heparan sulphate. A method is proposed for suppressing tumour growth, based on blocking the human fibroblast growth factor/human fibroblast growth factor receptor type 1 (domains II and IIIc) pathway and involves administering the antibody. A conjugate of the antibody and contrast agents is proposed intended for use in diagnosing malignant and other growths, whose cells express large quantities of FGFR1. A method is proposed for diagnosing malignant neoplasms. The proposed methods enable blocking the fibroblast growth factor/fibroblast growth factor receptor type 1 pathway by means of binding to domains II and IIIc of FGFR1, thus stopping or slowing tumour growth. The methods present novel preparations for the diagnosis and treatment of diseases related to overproliferation and neovascularization.Type: ApplicationFiled: March 30, 2011Publication date: April 17, 2014Inventor: llya Valer'evich Tymofeev
-
Patent number: 8697071Abstract: The present invention relates to molecules comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are useful in preventing, treating, or ameliorating symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function mediated by Fc?R is desired, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.Type: GrantFiled: June 15, 2012Date of Patent: April 15, 2014Assignee: MacroGenics, Inc.Inventors: Jeffrey Stavenhagen, Sergey Gorlatov, Christopher Rankin, Nadine Tuaillon
-
Patent number: 8691232Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.Type: GrantFiled: January 21, 2011Date of Patent: April 8, 2014Assignee: Genentech, Inc.Inventors: Mika K. Derynck, Stephen M. Kelsey
-
Patent number: 8691229Abstract: The present invention relates to a method of using inhibitors of phospholipid scramblases (PLSCRs) for the prophylactic or therapeutic treatment of cancers. The PLSCR-inhibitors of the invention comprise compounds PLSCR-specific monoclonal antibodies, antagonists or nucleic acids, which have ability to decrease the level and/or biological activity of PLSCRs in cancer cells.Type: GrantFiled: April 20, 2012Date of Patent: April 8, 2014Assignee: Err-Cheng CHANInventors: Err-Cheng Chan, Hong-Arh Fan, Kuei-Tien Chen, Yung-Bin Kuo, Jinn-Shiun Chen, Chung-Wei Fan
-
Patent number: 8685395Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.Type: GrantFiled: March 7, 2013Date of Patent: April 1, 2014Assignee: ZymoGenetics, Inc.Inventors: Yue Yao, Janine Bilsborough
-
Patent number: 8679497Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo.Type: GrantFiled: May 7, 2012Date of Patent: March 25, 2014Assignee: Eli Lilly and CompanyInventors: Donmienne Doen Mun Leung, Peng Luan, Joseph Vincent Manetta, Ying Tang, Derrick Ryan Witcher
-
Patent number: 8679503Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.Type: GrantFiled: July 12, 2010Date of Patent: March 25, 2014Assignee: Yale UniversityInventors: Jack A. Elias, Zhou Zhu
-
Patent number: 8679493Abstract: Methods and compositions involving polypeptides having an aglycosylated antibody Fc domain. In certain embodiments, polypeptides have an aglycosylated Fc domain that contains one or more substitutions compared to a native Fc domain. Additionally, some embodiments involve an Fc domain that is binds some Fc receptors but not others. For example, polypeptides are provided with an aglycosylated Fe domain that selectively binds Fc?RI at a level within 2-fold of a glycosylated Fc domain, but that is significantly reduced for binding to other Fc receptors. Furthermore, methods and compositions are provided for promoting antibody-dependent cell-mediated toxicity (ADCC) using a polypeptide having a modified aglycosylated Fc domain and a second non-Fc binding domain, which can be an antigen binding region of an antibody or a non-antigen binding region. Some embodiments concern antibodies with such polypeptides, which may have the same or different non-Fc binding domain.Type: GrantFiled: June 30, 2010Date of Patent: March 25, 2014Assignee: Research Development FoundationInventors: George Georgiou, Sang Taek Jung, Sai Reddy
-
Publication number: 20140079628Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.Type: ApplicationFiled: September 20, 2012Publication date: March 20, 2014Inventors: G. Mark Anderson, Bernard Scallon, Michael Naso, Ann Cai, Cam Ngo
-
Patent number: 8673305Abstract: The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5a to C5aR and functional consequences of neutrophil chemoattractant receptor activation.Type: GrantFiled: June 15, 2012Date of Patent: March 18, 2014Assignee: G2 Therapies LtdInventor: Charles Reay MacKay
-
Patent number: 8673302Abstract: The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to antibodies capable of binding to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding processes, for detecting and diagnosing pathological hyperproliterative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the overexpression of cMet. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers.Type: GrantFiled: August 23, 2010Date of Patent: March 18, 2014Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Alexandra Jouhanneaud
-
Publication number: 20140072552Abstract: The present invention provides antibodies or antigen-binding fragments thereof that specifically bind the ENDO180 polypeptide and are internalized thereby, to conjugates comprising the molecules, to compositions comprising the antibodies and conjugates and to methods of using the same for delivery of therapeutic agents to cells that express the ENDO180 polypeptide on the surface of the cell for treating cell proliferative diseases or disorders and fibrosis, and for controlling (modulating) tumor progression.Type: ApplicationFiled: May 2, 2013Publication date: March 13, 2014Applicant: QUARK PHARMACEUTICALS, INC.Inventor: Elena Feinstein
-
Patent number: 8668910Abstract: The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate.Type: GrantFiled: September 30, 2010Date of Patent: March 11, 2014Assignee: SanofiInventors: Herve Bouchard, Alain Commercon, Claudia Fromond, Vincent Mikol, Fabienne Parker, Ingrid Sassoon, Daniel Tavares
-
Publication number: 20140065094Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: ApplicationFiled: December 27, 2012Publication date: March 6, 2014Applicant: Creabillis Therapeutics S.P.A.Inventors: Silvio TRAVERSA, Chiara LORENZETTO, Valentina MAINERO, Sebastiano MORENA, Silvano FUMERO, Luca BECCARIA
-
Patent number: 8663640Abstract: The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides the use of an antibody composition with two distinct non-overlapping binding specificities to human EGFR. The antibody composition is effecting in treating cancer following treatment with other anti-EGFR antibodies, whether the cancer shows progression during or following the prior treatment or not. The antibody composition can also be used for repeated treatment of recurrent tumors following first-line therapy with the antibody composition of the invention, as the composition does not lead to selection of resistant tumors. A further therapeutic use is the use of an antibody composition of the invention for treatment of cancer that is resistant to known anti-EGFR antibodies.Type: GrantFiled: August 27, 2009Date of Patent: March 4, 2014Assignee: Symphogen A/SInventors: Mikkel Wandahl Pedersen, Michael Kragh, Adam S. Hey, Helle Jacobsen
-
Patent number: 8663634Abstract: The present invention provides methods of treating, preventing or ameliorating the symptoms of T cell-mediated immunological diseases, particularly autoimmune diseases, through the use of anti-CD3 antibodies. In particular, the methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the invention provides for modification of the anti-CD3 antibodies such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-CD3 antibodies.Type: GrantFiled: July 11, 2006Date of Patent: March 4, 2014Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Ronald Wilder, Ezio Bonvini, Leslie S. Johnson
-
Patent number: 8663641Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.Type: GrantFiled: September 14, 2012Date of Patent: March 4, 2014Assignee: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
-
Publication number: 20140056882Abstract: The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of pulmonary diseases characterized by or associated with infiltration of neutrophils and complications arising therefrom. The present invention further provides agents and pharmaceutical compositions comprising agents which inhibit the activity of G-CSF or its receptor, interfere with G-CSF signaling and/or which down-regulate expression of G-CSF or its receptor.Type: ApplicationFiled: October 1, 2013Publication date: February 27, 2014Applicant: CSL LIMITEDInventors: David Eric CRUMP, Andrew Donald NASH
-
Patent number: 8658168Abstract: This invention discloses monoclonal antibodies (MAbs) which have little or no signaling activity as monomers become potent anti-tumor agents when they are converted into homoconjugates. The homoconjugates exert anti-growth activity by signaling G0/G1 arrest or apoptosis, depending upon which cell surface molecule they bind. This activity is specific and does not require an Fc portion. These conjugates are potent, anti-tumor agents.Type: GrantFiled: April 8, 2002Date of Patent: February 25, 2014Assignee: The Board of Regents of The University of Texas SystemInventors: Maria-Ana Ghetie, Jonathan W. Uhr, Ellen S. Vitetta
-
Patent number: 8658165Abstract: The present invention relates to modulators of the Neuregulin (NRG) family, particularly NRG1 and more particularly NRG1?, and most particularly NRG1?1. The present invention also relates to the use of such modulators to inhibit goblet cell hyperplasia and therefore also relates to the use of such modulators in the treatment or prevention of human diseases and disorders featuring pathological mucus production such as COPD, CF, chronic bronchitis and asthma.Type: GrantFiled: August 7, 2012Date of Patent: February 25, 2014Assignee: Novartis AGInventors: Carol Elizabeth Jones, Alan Jackson
-
Patent number: 8658171Abstract: The present invention provides a humanized anti-TNF monoclonal antibody and the use thereof. The humanized anti-TNF monoclonal antibody significantly reduces the immunogenicity of murine-antibody while retaining the ability of antibody to recognize antigen, compared with conservative mouse chimeric antibody. Therefore, safety of the antibody in clinical applications has been improved.Type: GrantFiled: February 24, 2012Date of Patent: February 25, 2014Assignee: Livzon Mabpharm Inc.Inventors: Baoguo Zhu, Desheng Tao, Bill Nai-Chau Sun, Lee-Hwei King Sun, Ruey Shyan Liou, Cecily Rou-Yun Sun, Qiang Li, Yucai Peng, Jingwei Zhang, Zhenxiang Hu
-
Patent number: 8658175Abstract: The present invention relates to antibodies directed to EGFR and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of EGFR.Type: GrantFiled: October 28, 2010Date of Patent: February 25, 2014Assignee: AbbVie Biotherapeutics Inc.Inventors: Robert B. Dubridge, David B. Powers, Charles M. Forsyth